Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Debt (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-Current Debt for 3 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 40.41% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a 40.41% increase, with the full-year FY2025 number at $9.7 million, up 40.41% from a year prior.
  • Non-Current Debt was $9.7 million for Q4 2025 at Kura Oncology, up from $5.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $9.7 million in Q4 2025 to a low of $5.3 million in Q3 2025.
  • A 3-year average of $8.2 million and a median of $8.9 million in 2023 define the central range for Non-Current Debt.
  • Biggest YoY gain for Non-Current Debt was 40.41% in 2025; the steepest drop was 31.21% in 2025.
  • Kura Oncology's Non-Current Debt stood at $9.3 million in 2023, then dropped by 25.89% to $6.9 million in 2024, then surged by 40.41% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Non-Current Debt are $9.7 million (Q4 2025), $5.3 million (Q3 2025), and $6.5 million (Q2 2025).